Regor Therapeutics

Computer Accelerated Rational Discovery

RGT-419B Clin1 breast cancer; RGT-264 Clin1 solid tumors; RGT-028 Clin0 metabolic condition; RGT-274 Clin0 metabolic condition; RGT-587 Clin0 oncology; RGT-018 Clin0 oncology; RGT-118 Clin0 autoimmune condition

Regor Therapeutics is a clinical-stage company focused on discovering and developing innovative medicines for a range of therapeutic areas, including oncology, immunology, and metabolic disorders. Their proprietary CARD (Computer Accelerated Rational Discovery) platform enables them to efficiently identify and develop novel drug candidates. Regor Therapeutics is developing targeted therapies for various cancer types, immune-mediated disease, and metabolic disorders. Their two lead products are RGT-075, a highly selective oral GLP-1 agonist being developed for the treatment of obesity and related metabolic disorders, and RGT-419B, a CDK4 inhibitor being investigated for the treatment of breast cancer.